Banco Bilbao Vizcaya Argentaria, S.A. vs Johnson & Johnson: Strategic Comparison

This in-depth comparison examines Banco Bilbao Vizcaya Argentaria, S.A. and Johnson & Johnson across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Banco Bilbao Vizcaya Argentaria, S.A. on its own, evaluating Johnson & Johnson, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Banco Bilbao Vizcaya Argentaria, S.A. and Johnson & Johnson is widest.

On the headline numbers, Banco Bilbao Vizcaya Argentaria, S.A. reports annual revenue of $42.5B against $94.2B for Johnson & Johnson, while their respective market capitalizations stand at $88.5B and $612.8B. Banco Bilbao Vizcaya Argentaria, S.A. is headquartered in Spain and Johnson & Johnson operates from United States, and those different home markets shape how each company competes.

Banco Bilbao Vizcaya Argentaria, S.A.: BBVA grew from Bilbao banking roots into a global financial group through mergers, privatizations, and expansion into Mexico and Turkey. Its current identity is defined by digital banking scale and the tension between emerging-market returns and macro volatility.

Johnson & Johnson: Johnson & Johnson began as a medical-products company in the nineteenth century and became a diversified healthcare giant. After the Kenvue separation, it is a more focused healthcare company centered on medicine and medical technology.

Banco Bilbao Vizcaya Argentaria, S.A. and Johnson & Johnson pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Banco Bilbao Vizcaya Argentaria, S.A. and Johnson & Johnson.

Banco Bilbao Vizcaya Argentaria, S.A. business model: BBVA makes money primarily from net interest income on loans and deposits, plus fees, cards, payments, asset management, insurance, trading income, and corporate banking. Its customer base spans retail clients, SMEs, corporates, public-sector borrowers, and digital-only banking users.

Johnson & Johnson business model: Johnson & Johnson makes money by discovering, developing, manufacturing, and selling prescription medicines and medical technologies. Innovative Medicine sells therapies in oncology, immunology, neuroscience, pulmonary hypertension, infectious disease, and cardiovascular/metabolism. MedTech sells surgery, orthopaedics, cardiovascular, and vision products to hospitals, physicians, and healthcare systems.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Banco Bilbao Vizcaya Argentaria, S.A. stack up against those of Johnson & Johnson.

Banco Bilbao Vizcaya Argentaria, S.A. competitive advantage: BBVA's advantage is a high-return Mexico franchise, strong digital adoption, disciplined capital management, and a multi-country retail and corporate banking platform.

Johnson & Johnson competitive advantage: Johnson & Johnson's advantage comes from scale, R&D depth, global regulatory capability, major oncology and immunology franchises, MedTech breadth, and a large commercial infrastructure.

Future prospects matter as much as current results. The growth strategies below explain how Banco Bilbao Vizcaya Argentaria, S.A. and Johnson & Johnson each plan to expand from here.

Banco Bilbao Vizcaya Argentaria, S.A. growth strategy: The growth strategy is to acquire customers digitally, deepen relationships with payments and lending, keep Mexico as a high-return engine, and expand European digital banking without building a costly branch-heavy footprint.

Johnson & Johnson growth strategy: The company is investing in oncology, immunology, neuroscience, cardiovascular MedTech, electrophysiology, surgery, R&D, acquisitions, and global commercial execution.

A closer look at the financial trajectory of Banco Bilbao Vizcaya Argentaria, S.A. and Johnson & Johnson rounds out the comparison.

Banco Bilbao Vizcaya Argentaria, S.A.: For FY2025, BBVA reported EUR36.931B in gross income, EUR26.280B in net interest income, and EUR10.511B in net attributable profit. The site stores the native figures and shows about $42.5B of comparable revenue and about $12.1B of net attributable profit using its USD convention.

Johnson & Johnson: Johnson & Johnson's FY2025 sales increased 6.0% to $94.193 billion. Net earnings rose to $26.804 billion, helped by operating performance and other income items. Innovative Medicine generated $60.401 billion in sales, while MedTech generated $33.792 billion.